Contents lists available at ScienceDirect

## Integrative Medicine Research



**Review Article** 

# Acupuncture as an alternative or in addition to conventional treatment for chronic non-specific low back pain: Systematic review and meta-analysis



Carlo Maria Giovanardi<sup>a,1</sup>, Marien Gonzalez-Lorenzo <sup>b,\*</sup>, Alessandra Poini<sup>c</sup>, Eleonora Marchi <sup>d</sup>, Antonio Culcasi<sup>e</sup>, Francesco Ursini<sup>e,f</sup>, Cesare Faldini<sup>f,g</sup>, Alberto Di Martino <sup>f,g</sup>, Umberto Mazzanti <sup>a</sup>, Emanuela Campesato<sup>h</sup>, Annunzio Matrà<sup>a</sup>, Sabina Cevoli<sup>i</sup>, Maria Grazia Benedetti<sup>d,f</sup>

<sup>a</sup> Italian Federation of Acupuncture Societies, Bologna, Italy

<sup>c</sup> Physical Medicine and Rehabilitation Unit, State Hospital - Republic of San Marino (SMR), Italy

<sup>d</sup> Physical Medicine and Rehabilitation Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

<sup>e</sup> Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

<sup>f</sup> Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum University of Bologna, Bologna, Italy

<sup>g</sup> 1st Orthopaedic and Traumatology Department, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

<sup>h</sup> UO Anaestesia and Pain Therapy Unit Melotti, Department of Emergency and Urgency, Bologna, Italy

<sup>i</sup> IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

#### ARTICLE INFO

Keywords: Acupuncture Chronic low back pain Conventional therapies Systematic review

### ABSTRACT

Background: Conventional therapies (CTs), pharmacological (PH) and non-pharmacological (NPH), do not always achieve benefits in the treatment of chronic low back pain (CLBP). We assessed efficacy and safety of acupuncture for CLBP as alternative or addition to CT.
Methods: We included randomised controlled trials (RCTs) comparing acupuncture alone or in combination with CT to CT. We searched Medline, Cochrane Library, Embase up to May 2022. We assessed risk of bias with the original Cochrane tool and GRADE certainty of evidence. Results were pooled through meta-analysis.
Results: Ten RCTs (2122 participants) were included comparing acupuncture versus CT and 6 (374 participants) comparing acupuncture plus CT to CT alone. Comparing acupuncture with NPH or PH, no differences were found for pain and disability. Comparing with combined PH and NPH, pain and disability were reduced (SMD=-0.71, 95%CI-0.62 to -0.37; SMD=-0.71, 95%CI-0.94 to -0.46; SMD=-0.95, 95%CI-1.36 to -0.54). Comparing

and disability were reduced (MD=-0.70, 95%CI-0.94 to -0.40; SMD=-0.95, 95%CI-1.36 to -0.34). Comparing acupuncture plus PH with PH alone, pain and disability were reduced (MD=-0.21,8 95%CI-433.28 to -10.42; MD=-3.1, 95%CI-4.87 to -1.83). Comparing acupuncture plus combined treatment versus combined treatment alone, no differences were found in pain, while disability was reduced (MD=-3.40 95%CI-5.17 to -1.63). No studies assessed adverse event. Certainty of evidence ranged from moderate to very low.

*Conclusion:* We are uncertain whether acupuncture is more effective and safer than CT. In the comparisons without estimates' imprecision, acupuncture showed promising results. Acupuncture could be an option based on patients' preferences.

#### 1. Introduction

Low back pain (LBP) is defined as pain, discomfort, muscle tension or stiffness localized below the costal margin and above the inferior gluteal folds. If it persists for more than three months and is not attributable to a recognizable specific pathology, it is defined as chronic non-specific low back pain (CLBP)<sup>1</sup> and it accounts for the majority of cases.<sup>2,3</sup> Chronic LBP is a major cause of disability in Western countries which results in a high socioeconomic burden, with an estimated USD 1.93 to 81.24 billion per person, adjusted in 2015, spent in developed countries.<sup>4</sup> A systematic review<sup>5</sup> estimates that the prevalence of CLBP

https://doi.org/10.1016/j.imr.2023.100972

Received 18 November 2022; Received in revised form 26 May 2023; Accepted 5 June 2023 Available online 7 July 2023 2213-4220/© 2023 Korea Institute of Oriental Medicine. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

<sup>&</sup>lt;sup>b</sup> Laboratorio di Metodologia delle Revisioni Sistematiche e Produzione di Linee Guida, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

<sup>\*</sup> Corresponding author at: Laboratorio di Metodologia delle Revisioni Sistematiche e Produzione di Linee Guida, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

E-mail address: mariengonzalezlorenzo@gmail.com (M. Gonzalez-Lorenzo).

<sup>&</sup>lt;sup>1</sup> The authors contributed equally to this work.

ranges from 5.9 to 18.1% and another Italian epidemiological study<sup>6</sup> reports a prevalence equal to 31.5%.

People affected with CLBP often require long-term treatment. Conventional therapies aim to resolve pain, improve quality of life and reduce disability, but they don't always achieve the expected results.<sup>4,7</sup> Non-pharmacological treatment options include exercise, acupuncture, spinal manipulation therapy (SMT), physiotherapy, cognitive-behavioral therapy, yoga, mindfulness, interdisciplinary rehabilitation and massage. Pharmacological options include paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, oral opioids, anticonvulsants, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs) and oral muscle relaxants.

None of these treatment options, however, can fully achieve the expected results. Paracetamol has proved to be ineffective and harmful;<sup>8,9</sup> the use of NSAIDs is associated with the risks of gastrointestinal, liver and cardiorenal toxicity.<sup>10</sup> Routine use of opioids is associated with the risks of overdose and addiction, and poorer long-term results have been observed.<sup>11,12</sup> Anti-seizure medications have been shown to be ineffective.<sup>13</sup> Muscle relaxants should be further investigated for short-term use.<sup>8</sup> Acupuncture can be a viable option in alternative or in addition to conventional therapy. Over the past few decades, the mechanisms of action of acupuncture have been widely investigated and neurobiological models have been developed to explain how this technique achieves its effects in many clinical applications including treatment of CLBP.

Several studies indicate that prolonged skin stimulation with needles inhibits transmission of pain by activating the gate-control system<sup>14</sup> and acting on the human limbic and basal forebrain areas which are thought to be involved in pain processing.<sup>15</sup> Acupuncture appears to activate the release of opioids in the central nervous tissue thus resulting in a long-lasting activation of the ascending sensory tracks and making it possible to relieve several pain conditions.<sup>16</sup> Advances in research have proved that acupuncture can modulate the release of adenosine, a neurotransmitter acting as a potent endogenous anti-inflammatory agent: adenosine is a signaling molecule in immunity and inflammation<sup>17</sup> that can regulate transmission of pain to the spinal cord and periphery.<sup>18</sup>

Two systematic reviews were recently published on acupuncture for the treatment of chronic low back pain. One is a Cochrane review<sup>4</sup> that compared acupuncture with sham acupuncture, no treatment, usual care and other treatments. In this review, usual care is considered as an unique entity without distinguishing between pharmacological and nonpharmacological components. Another systematic review<sup>19</sup> reported on 15 meta-analyses on different treatments. In this review, acupuncture was compared to placebo only.

In the light of the above, the objective of this systematic review was to assess the efficacy and safety of acupuncture for the treatment of chronic non-specific low back pain as an alternative or in addition to conventional therapy (pharmacological and or non-pharmacological treatment).

#### 2. Methods

We reported this systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplementary materials).<sup>20</sup>

#### 2.1. Inclusion criteria

#### 2.1.1. Participants

Adults ( $\geq$ 18 years) with chronic non-specific low back pain. Chronic non-specific low back pain was defined as pain occurring for more than three months, and not attributable to a recognizable specific pathology (e.g., infection, tumor, osteoporosis, lumbar spine fracture, structural deformity, inflammatory disorder, radicular syndrome, or cauda equina syndrome).<sup>1</sup>

#### 2.1.2. Intervention

Any treatment involving needle insertion (with or without manual or electrical stimulation) at acupuncture points, pain points or trigger points, described as acupuncture given alone on in addition to any pharmacological and or non-pharmacological treatments.

#### 2.1.3. Comparison

Any pharmacological and or non-pharmacological treatments alone.

#### 2.1.4. Outcomes

#### Primary outcomes:

- Pain intensity as measured by validated scales at the end of treatment.
- Disability as measured by validated scales at the end of treatment.
- Secondary outcomes.
- Quality of life as measured by validated scales (e.g., SF-36; SF-12). $^{21,22}$
- Functional state ad measured by validated scales.
- Use of analgesics (for the comparisons with non-pharmacological treatment).
- Number of subjects with at least one adverse event (AE).
- Dropout from treatment.

#### 2.1.5. Study design: randomized-controlled trials (RCTs)

We excluded studies that evaluated acupuncture at specific "microsystems" (e.g., scalp or ear acupuncture) and studies that evaluated other methods of stimulating acupuncture points without needle insertion, for example, acupressure, laser stimulation, or transcutaneous electrical stimulation, injected fluids at acupuncture or trigger points. We also excluded studies that compared acupuncture with "usual care", when the component of usual care (i.e., pharmacological, nonpharmacological or combined treatments were nor described.

#### 2.2. Search strategy

Cochrane Database of Systematic Reviews (CENTRAL), Embase, MEDLINE, and ClinicalTrial.gov were searched for eligible studies. Literature search was performed using free text and Thesaurus terms from inception up to 24 May 2022 without language restriction. The detailed search strategy is reported in the Supplementary Material. We identified other potentially eligible studies by searching the reference lists of included studies, systematic reviews and meta-analyses.

#### 2.3. Selection of studies and data extraction

Two authors (MGL, CMG) independently screened articles retrieved via the search strategy from the titles and abstracts. Potentially relevant studies were acquired in full text and assessed for final inclusion independently by two authors (MGL, CMG). Any disagreement was discussed with the other authors. Two review authors independently extracted data from the studies (MGL, CMG). We extracted the following information: number and characteristics of participants: mean age,% female, duration of disease in years, details of acupuncture treatments: number of sessions, number of acupoints, achievement of de-chi (an irradiating feeling considered to indicate effective needling), duration of treatment in weeks; details of control intervention, length of follow-up after the end of treatment, types of outcomes assessed, country where the study was conducted.

#### 2.4. Assessing the risk of bias

Two authors (MGL, CMG) independently assessed risk of bias according to the criteria set out in the Cochrane Handbook for Systematic Reviews of Interventions.<sup>23</sup> The following criteria were considered: sequence generation and allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome assessors (detection bias), incomplete outcome data (attrition bias), and selective outcome reporting (reporting bias). Disagreement between reviewers was resolved by discussion.

#### 2.5. Data synthesis

We analyzed dichotomous outcomes by calculating the risk ratio (RR) for each trial with the uncertainty in each result being expressed with a 95% confidence interval (CI). We analyzed continuous outcomes by calculating the mean difference (MD) with 95% CI when the studies used the same instrument for assessing the outcome. We used the standardized mean difference (SMD) when the studies used different instruments. We interpreted SMD values with the classification proposed by Cohen<sup>24</sup> where an effect size of 0.2 means a small effect, 0.5 means a medium effect, 0.8 means a large effect. As we supposed a certain degree of heterogeneity among studies, due to treatment schedules, way in assessing response criteria, risk of bias and other factors which may have affected direction and magnitude of treatment effect, we pooled data used the random effect model for each outcome. Seeking statistical heterogeneity among studies, the Cochrane Q-test was performed, with a significant threshold of alpha = 0.1 and inconsistency among studies was quantified by the I-squared statistic;<sup>23</sup> an I square >70% was judged a significant heterogeneity.

Results are depicted in all figures as conventional meta-analysis forest plots. RevMan 5.4 was used for producing forest plot figures.<sup>25</sup> We planned to use visual inspection of funnel plots (plots of the effect estimate from each study against the sample size or effect standard error) to indicate possible publication bias if there were at least 10 studies included in the meta-analysis.

Subgroup Analysis:

Although the STRICTA (Standards for Reporting Interventions in Controlled Trials of Acupuncture) recommendations describe the components of acupuncture procedures<sup>26</sup> better outcomes appear to be associated with a greater number of needles and treatment sessions<sup>27</sup> and on the other hand, an insufficient dose of acupuncture may be an obstacle to good patient care.<sup>28</sup> We established standard criteria to define the adequate dose of acupuncture, as already expressed by other authors,<sup>29,30</sup> considering the following three parameters:

- number of points needled during each treatment,
- de-qi response,
- number of treatment sessions.

The "de qi" response, that is the sensation from needling experienced by the patient, may be reported as numbness (A-beta fiber activation) or as aching, dull, heavy, and warm sensation (A-delta or C fiber activation).<sup>31</sup> The concept of dose-intensity has thus been introduced and used to group the studies according to the intensity of acupuncture based on the following criteria:

- number of sessions ( $\geq 8$  vs. <8),
- number of acupoints treated ( $\geq 10$  vs. <10),
- · achievement of de-qi (yes vs. no/not reported).

Acupuncture was judged as at low intensity if only one criterion was met; on medium intensity if two criteria were met; high intensity if all the three criteria were met. We planned to conduct subgroup analyses for intensity of acupuncture. However, due to the small number of included studies in each analysis, subgroup analysis was not possible.

#### 2.6. Grading of evidence

We assessed the overall certainty of the evidence for the primary outcomes using the five GRADE domains (study limitations, consistency of effect, imprecision, indirectness, and publication bias) according to the GRADE approach.<sup>32</sup> Based on the above domains, the GRADE system uses the following criteria to grade the evidence: High: we are very

confident that the true effect lies close to that of the estimate of the effect. Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. The existing evidence was summarized in a "Summary of Findings" table that provides key information about the magnitudes of relative and absolute effects of the interventions, the amount of available evidence and the certainty of available evidence.<sup>33</sup>

#### 3. Results

#### 3.1. Search results

The bibliographic search retrieved 596 records after duplicates were removed. Thirty-six studies were judged as potentially relevant. Twentytwo articles were excluded because they did not meet the inclusion criteria, references of excluded studies and reasons for exclusion are described in the Supplementary material. Fourteen randomized trials were finally included.<sup>34-47</sup> We grouped the included studies in two main groups: 1) acupuncture alone: studies comparing acupuncture to conventional therapy (pharmacotherapy, non-pharmacologic treatments, combination of pharmacologic and non-pharmacologic treatments); 2) acupuncture as add-on to conventional treatment: studies comparing acupuncture in addition to conventional therapy to conventional therapy alone. Ten studies assessed the efficacy and safety of acupuncture alone and six assessed the efficacy of acupuncture as add-on to conventional therapy (Fig. 1).

#### 3.2. Characteristics of the included studies

Two studies<sup>38,47</sup> provided data for both the comparisons. The trials included a total 2440 participants; mean age ranged from 33 to 81 years, two studies did not report this information; mean percentage of female (ranged from 23% to 90%), three studies did not report this information; mean percentage of participants with chronic pain for at least one year ranged from 61% to 75% in five studies; four studies reported a mean duration of back pain of 8.1 (SD 8),<sup>37</sup> 6.9 (SD NR),<sup>47</sup> 9.6,<sup>43</sup> 9.9<sup>44</sup> years respectively and one of 22 months,<sup>40</sup> four studies did not report this information.<sup>36,38,39,46</sup> Mean duration of treatments ranged from 3 to 12 weeks Three studies were conducted in US, three in Germany and one each in Japan, Taiwan, India, Hong Kong, Lebanon, China, Iran and UK.

The scales used in the studies to measures the outcomes were: pain intensity: Visual analogue scale (VAS) 0–10 or 0–100,<sup>48</sup> Von Korff Chronic Pain Grade Scale (CPGS);<sup>49</sup> disability: Roland Morris Disability Questionnaire,<sup>50</sup> Hannover Functional Ability Questionnaire,<sup>51</sup> Oswestry disability index,<sup>52</sup> Pain disability index;<sup>53</sup> functional state: Aberdeen Low back pain;<sup>54</sup> quality of life: SF –36 total,<sup>21</sup> SF-12 physical health, SF-12 mental health.<sup>22</sup>

*Types of comparisons*: Among the studies included in group "acupuncture alone", four studies compared acupuncture with non-pharmacologic treatment: massage,<sup>34</sup> TENS,<sup>36,38</sup> pulse radiofrequency;<sup>39</sup> three studies compared acupuncture with pharmacologic treatment (baclofen<sup>47</sup> ibuprofen<sup>41</sup> drugs not described<sup>39</sup>).

Among the studies included in group "acupuncture as add-on to conventional therapy", four assessed the addition of acupuncture to non-pharmacologic treatment compared non-pharmacologic treatment alone: exercise,<sup>45</sup> TENS,<sup>38</sup> active physiotherapy,<sup>43</sup> physiotherapy, back school, mud packs, infrared heat therapy;<sup>44</sup> one assessed the addition of acupuncture to combined pharmacologic and non-pharmacologic treatment (NSAIDs, muscle relaxants, paracetamol and back exercises) compared to combined treatment alone;<sup>46</sup> one study compared the addition




Fig. 1. PRISMA Flow diagram.

of acupuncture to pharmacologic treatments compared to pharmacologic treatment alone<sup>47</sup> (Table 1).

#### 3.3. Risk of bias of included studies

Six studies were judged at low risk of selection bias because both the methods for random sequence generation and allocation concealment were appropriate;<sup>35-37,44,46,47</sup> six studies<sup>34,38,40-42,45</sup> followed ad adequate method for random sequence generation but did not provide information about concealment of allocation. The remaining two studies<sup>43,39</sup> were judged at unclear risk for selection bias because they did not provide any information about randomization procedure and allocation concealment. All the studies were judged at high risk of both performance and detection bias because they were open label. Three studies were judged at high of attrition bias<sup>38,43,46</sup> because of the high number of subjects who dropped out from studies. The study protocol was available only for three studies<sup>35,37,47</sup> and the outcomes reported in the final publication coincided with the outcomes listed in the protocol; for all the remaining studies the protocol was not available, and they were judged at unclear risk of selective outcome reporting (Fig. 2. Risk of bias summary: Review authors' judgments of bias items for each included study). Table 1

Characteristics of RCTs of acupuncture compared to several controls in patients with chronic low back pain (CLBP).

$ \begin{array}{c} \mbox{Cherkin} (2001)^{15} & 122 (59%) NS-CLBP & (A) AT (10 sections, 10 & (B) Massage (n = 78) & Disability & Y \\ \mbox{Cherkin} (2009)^{16} & 479 (63%) NS-CLBP & (A) AT (5 + 0 sections, 3 & (B) Usal care & Disability & Y \\ \mbox{Cherkin} (2009)^{16} & 479 (63%) NS-CLBP & (A) AT (5 + 0 sections, 3 & (B) Usal care & Disability & Y \\ \mbox{Cherkin} (2009)^{16} & 479 (63%) NS-CLBP & (A) AT (5 + 0 sections, 4 weeks, 10 & (B) Usal care (drugs, 7 = 34) & Drop-out & $	Funding Note
S44.9 NR $(3%)$ weeks, de-j, $n = 94$ ) $(3%)$ Drop-ont $(3%)$ Lackin (2009)**476 (63%) NS-CLBP (7/NR 	
63%         52 weeks madium         52 weeks madium         52 weeks madium         52 weeks madium         53 weeks madium         54 weeks madium         54 weeks madium         56 weeks madium         56 weeks madium         57 weeks madium         610 Waal care madium         Disability madium         Y           rrant (1999) <sup>177</sup> 60 (90%) NS-CLBP         (A) AT (28 sessions, 4 weeks, madium         (B) TENS (n = 28)         Pain         Y           rsake (2007) <sup>28</sup> 775 (57.4%) NS-CLBP         (A) AT (10-15 sessions, 37 weeks, NR deq. (n = 337)         (B) Usual care (drugs, physical therapy, an = 161)         Pain         Y           rsmany         50.4/8.1         2.2 weeks         (B) Usual care (drugs, physical therapy, an = 161)         Pain         Y           rsmany         50.4/8.1         2.3 weeks         (B) Usual care (drugs, physical therapy, an = 161)         Pain         Y           rsmany         NR         4.4 (10-15 sessions, 3 weeks, madium         (B) Pals radiofrequercy (c) 180 (NS CLBP         (A) AT (10-15 sessions, 4 weeks, low         (B) Pals radiofrequercy (c) 180 (alwas) therapy, an = 161)         Pain         N           uita         91 (50 (50%) NS CLBP         (A) AT (10-15 sessions, 7 weeks, NR         (B) At (10 sessions, 7 weeks, NR         (B) At (10 sessions, 7 weeks, nedium         (B) At (10 sessions, 7 weeks, madium         (B) Massage, physical therapy and iburgroten na	Yes
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
Enchain (2009)**         476 (53%) NS-CLEP         (A) AT (3-10 seasions, 8         (B) Usual care         Disability         Y           NS         47,000         52         vecks, 40, - a 315)         care, and physical         Dop-out         Pain         Y           yran (1999)*7         60 (90%) NS-CLEP         (A) AT (3 sessions, 40 vecks, 100         (B) Usual care (and physical         Pain         Y           yran (1999)*7         50 (45%) NS-CLEP         (A) AT (10-15 sessions, 100         (B) Usual care (and physical         Pain         Y           iatake (2007)*6         75 (57,4%) NS-CLEP         (A) AT (10-15 sessions, 100         (B) Usual care (and physical         Pain         Y           iatake (2010)*6         NR         24 vecks         (B) Poiscical Horapy, and Disability         Y           iatake (2010)*6         NR         (A) EA (12 sessions, 4 vecks, 100         (B) Usual care (and physical horapy, and Disability         Y           iatawan         NR, NS         NR         NR         NR         NR         NR           iatawan         S5 (J, S3         NR         (A) AT (10-sessions, 3 wecks, 100         (B) decosth (20 mg physical         Pain         N           indical         37, NR         S6 (30%) NS-CLBP         (A) AT (13 sessions, 4 wecks, 100         (B) AT (10 sessions, 4	
JS         47.NR 63%         weeds, d=q1, n = 315 24 weeds medium         (medium) medium, n = 101 medium, n = 101 mean, n = 101 medium, n = 101 medium, n = 101 mean, n = 1	Yes
63%         52 weeks         care, and physical         care, and physical           Jrant (1999) <sup>17</sup> 66 (00%) NS-CLBP         (A) AT (8 sessions, 4 weeks, 10)         (B) TENS (n = 28)         Prop-out         Prop-out           Hake (2007) <sup>18</sup> 775, (57, 4%) INS-CLBP         (A) AT (10 - 55 sessions, 10)         (B) Usual care (drugs, 10)         Pain         Y           Hake (2007) <sup>18</sup> 775, (57, 4%) INS-CLBP         (A) AT (10 - 15 sessions, 10)         (B) Usual care (drugs, 10)         Pain         Y           Jar (2010) <sup>16</sup> 100 (NR) NS-CLBP         (A) EA (12 sessions, 4 weeks, 10)         (B) Usual care (drugs, 10)         Pain         N           Jar (2011) <sup>11</sup> 60 (63%) NS-CLBP         (A) EA (12 sessions, 3 weeks, 10)         (D) Valdecoxib (20 ng 10)         Pain         N           Shankar (2011) <sup>11</sup> 60 (63%) NS-CLBP         (A) EA (10 sessions, 7 weeks, 10)         (D) days) plus         prop-out         Pain         N           Yam (2012) <sup>114</sup> 137 (23%) NS-CLBP         (A) AT (13 sessions, 7 weeks, 10)         (B) Care, 10 (A) (A)         Pain         N           Yam (2012) <sup>114</sup> 137 (23%) NS-CLBP         (A) AT (10 sessions, 7 weeks, 10)         (B) AT (10) (A)         Pain         N           Yam (2012) <sup>114</sup> 137 (23%) NS-CLBP         (A) AT (10) sessions, 5 weeks, 10) </td <td>165</td>	165
medium         therapy, n = 161)           Gor (099)         75.5/NR         12 weeks           35 (Men tablet of medication)         12 weeks           12 weeks         (h) TTS sessions, 4 weeks,           Germany         75.5/R           NR         24 weeks           NR         24 weeks           Iow         (h) AT (10-15 sessions, 4 weeks,           Germany         10 (N) NS-CLBP           NR         (A) AT (10-15 sessions, 4 weeks,           Germany         10 (N) NS-CLBP           NR         (A) EA (12 sessions, 4 weeks,           Germany         10 (N) NS-CLBP           NR         (A) EA (12 sessions, 4 weeks,           Germany         137 (22%) NS-CLBP           NR         NR           NR         NR           NR         25 / 1.83           W12 (212) <sup>41</sup> 137 (22%) NS-CLBP           NR         AD (A) T (13 sessions, 4 weeks,           Matient         (B) Matesage, physical           Prin         NR           Matesage         (A) AT (12 sessions, 4 weeks,           AD (A) T (12 sessions, 14 weeks,         (B) Massage, physical           Matesage         Pain         NR           Adw         2	
Grant (1999) <sup>70</sup> (KK         60 (00%) NS-CLBP         (A) AT (8 sessions, 4 vecks, or solution         (B) TENS (n = 28) (n = 327)         Pain prop-out         Ya           itake (2007) <sup>86</sup> (Germany         75 (57.4%) NS-CLBP         (A) AT (10-15 sessions, NR         (I) Usual care (drugs, physical therapy, and itake (2010) <sup>96</sup> Pain (I) Usual care (drugs, physical therapy, and itake (2011) <sup>91</sup> Pain (I) Usual care (drugs, physical therapy, physical therapy, physical therapy physical therapy phin         Pain phin         N           Chana         54, VRA         64, O, A T (12 sessions, 5 weeks, nedium         (B) Acrive physiotherapy, back physical therapy phin <td< td=""><td></td></td<>	
UK $35,5/NR$ NR deqi, $n = 32$ ) lowDrop-outHake (2007)** $75,57,4%$ ) NS-CLBP(A) AT (10-15 sessions, 12 weeks low(B) Usual care (drugs, path of the argay, and path of the argay, and 	Yes
35 (Mean tablet of medication)12 weeks lowHaake (2007)***775 (57.4%) NS-CLBP(A) AT (10-T5 sessions, 3 S-7weeks, NR (eq. i, n = 387) low recrise, n = 388)Physical therapy, and physical therapy, and physical therapy, and physical therapy and physica	
Hanke (2007) <sup>16</sup> Germany 50.4/8.1 NR Lin (2010) <sup>16</sup> 100 (NR) NS-CLBP Taiwan NR NR NR NR NR NR NR NR NR NR	
Germany Init (2010)***50.4/8.1 NR5-7 weeks, M de.qi, $n = 387$ 24 weeks low (A) L (2 sessions, 4 weeks, excrets, $n = 380$ ) (B) Puble radiofrequency (B) Puble radiofrequency (D) Medications ( $n = 35$ )Disability Drop-outInit (2010)*** Taiwan00 (NR) NS-CLBP NR(A) EA (12 sessions, 4 weeks, medium(B) Puble radiofrequency (D) Medications ( $n = 35$ )Pain Disability Drop-outNShankar (2011)*** India60 (63%) NS-CLBP S5.7.1.83(A) EA (10 sessions, 3 weeks, needium(B) Valdecoxib (20 mg supervised physiotherapy (3 weeks)Pain Drop-outNShankar (2011)*** India60 (63%) NS-CLBP (A) AT (23%) NS-CLBP(A) AT (13 sessions, 7 weeks, needium(B) Massage, physical therapy and medications (NPain NNYun (2012)*** Ur (2012)***187 (23%) NS-CLBP (A) AT (12 sessions, 7 weeks, How (A) AT (12 sessions, 7 weeks, (A) AT (10 sessions, 7 weeks, (A) AT (10 sessions, 5 weeks, high(B) Massage, physical therapy and medications (nPain NYun (2012)*** Ur (2012)***226 (30%) NS-CLBP (A) AT (10 sessions, 5 weeks, Horapy NR(B) AT (10 sessions, 5 weeks, (n = 74)(B) Baclofen (30 mg/day, Drop-outPain Disability Drop-outNZaringhalam (2010)*** Io weeks66 (NR) NS-CLBP (A) AT (10 sessions, 5 weeks, Horapy (B) AT (plus (C) (n = 8)) High(B) AT (10 sessions, 5 weeks, Herapy and buporfen Drop-outPain Disability Drop-outNLeibing (2002)*** Germany24 (NR) NS-CLBP (A) AT (12 sessions, 5 weeks, High(B) AT (10 sessions, 5 weeks, Hig	
NR24 weekscarcrise, $n = 388$ )Drop outLin (2010) <sup>10</sup> 100 (NR) NS-CLBP(A) EA (12 sesions, 4 weeks, de-qi, $n = 39$ )(B) Pulse radiofrequency (n = 29)Pain DisabilityNShankar (2011) <sup>11</sup> 60 (63%) NS-CLBP(A) EA (10 sessions, 3 weeks, medium(B) Valdecoxib (20 mg pupervised physiotherapy (3 weeks)Pain Drop-outNShankar (2011) <sup>21</sup> E6 (23%) NS-CLBP(A) AT (13 sessions, 7 weeks, medium(B) Valses, physical physiotherapy (3 weeks)Pain Drop-outNYun (2012) <sup>23</sup> E17 (23%) NS-CLBP(A) AT (13 sessions, 7 weeks, medium(B) Massage, physical therapy and medications physiotherapy and medications prop-outPain Drop-outNYun (2012) <sup>24</sup> 236 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, medium(B) Massage, physical therapy and medications prop-outPain Disability Drop-outNZaringhalam (2010) <sup>46</sup> 60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, medium(B) At (10 sessions, 5 weeks, medium(B) Baclofen (30 mg/day, n = 20)Pain Disability Drop-outNItahS4,5/6.9(B) AT (10 sessions, 5 weeks, medium(B) At (10 sessions, 5 weeks, medium(B) At (10 sessions, 5 weeks, medium(B) Attrie physiotherapy mediumPain NNItahS4,5/6.9(A) AT (10 sessions, 5 weeks, medium(B) Attrie physiotherapy mediumPain NNItahS4,5/6.9(A) AT (10 sessions, 5 weeks, medium(B) Attrie physiotherapy painPain NNItah <t< td=""><td>Yes</td></t<>	Yes
lowl	
Lint (2010)***100 (NR) NS-CLBP(A) EA (12 sestions, 4 weeks, (n = 39) MA (C) Medications (n = 35) Drop-outPain Disability Drop-out Ma Drop-outNRShankar (2011)***60 (63%) NS-CLBP(A) EA (10 sestions, 3 weeks, (C) Medications (n = 35) Drop-out Ma BD for 10 days) plus Durp-out mediumBD for 10 days) plus Drop-out mediumPain Drop-out Ma Drop-outPain NRYun (2012)***F7 (23%) NS-CLBP(A) AT (13 sestions, 7 weeks, (C) AT (13 sestions, 7 weeks, (NA T (13 sestions, 7 weeks, (NADD) (n = 63)Pain Drop out Drop out mediumNa Massage, physical Drop out mediumPain NNa Massage, physical Drop out mediumPain NYun (2012)***236 (30%) NS-CLBP(A) AT (12 sestions, 4 weeks, (NADD) (n = 63)(B) Massage, physical Drop out Massage, physical Massage, physical Pain NPain NNa NZaringhalam (2010)***60 (NR) NS-CLBP(A) AT (12 sestions, 5 weeks, (B) AT plus (C) (n = 20) Drop-out 10 weeks medium(B) Baclofen (30 mg/day, n = 20) Drop-out Disability Drop-out Drop-out Drop-out 10 weeks medium(B) Atrive physiotherapy Drop-out Drop-out Disability Drop-out Drop-	
TaiwanNR/NRde qi, $n = 39$ ) medium $(n = 29)$ (C) Medications $(n = 35)$ Disability Drop-outShankar (2011) <sup>11</sup> 60 (63%) NS-CLBP(A) EA (10 sessions, 3 weeks, nedium(B) Valdecoxib (20 mg supervised physiotherapy (3 weeks)Pain mediumNShankar (2011) <sup>11</sup> 60 (63%) NS-CLBP(A) EA (10 sessions, 7 weeks, nedium(B) Valdecoxib (20 mg supervised physiotherapy (3 weeks)Pain mediumNYun (2012) <sup>12</sup> 187 (23%) NS-CLBP(A) AT (18 sessions, 7 weeks, de qi, $n = 124$ )(B) Massage, physical therapy and medicationsPain DisabilityNYun (2012) <sup>12</sup> 236 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, and physical therapy 24 weeks(B) Massage, physical therapy and ibuprofen DisabilityPain DisabilityNYun (2012) <sup>12</sup> 236 (30%) NS-CLBP(A) AT (10 sessions, 5 weeks, and physical therapy 24 weeks(B) Massage, physical therapy and ibuprofen DisabilityPain DisabilityNZaringhalam (2010) <sup>44</sup> 60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, de qi, $n = 20$ )(B) Belofen (30 mg/day, Drop-outPain Drop-outNItoh (2009) <sup>130</sup> Tapan24 (NR) NS-CLBP(A) AT (12 sessions, 5 weeks, low(B) TENS $(n = 8)$ Pain Disability Drop-outNLeibing (2002) <sup>144</sup> Germany86 (57%) NS-CLBP(A) AT (20 sessions, 5 weeks, ligh(B) AT, Plus (C) $(n = 8)$ (B) Atrive physiotherapy lighPain PainNMolsberger (2002) <sup>145</sup> Germany86 (57%) NS-CLBP(A) AT (20 sessions, 4 weeks, ligh <t< td=""><td></td></t<>	
NRNA medium(C) Medications $(n = 35)$ Drop-out mediumShankar (2011) <sup>11</sup> 60 (63%) NS-CLBP (Alia(A) EA (10sessions, 3 weeks, nR(B) Valdecoxib (20 mg supervised physiotherapy (3 weeks)Pain Drop-outDrop-out supervised physiotherapy (3 weeks)Yun (2012) <sup>12</sup> 187 (23%) NS-CLBP (China 34/NR 40%(A) AT (18sessions, 7 weeks, edium(B) Massage, physical terapy and medications Drop outPain Drop-outNYun (2012) <sup>12</sup> (1na (236 (30%) NS-CLBP (214)236 (30%) NS-CLBP (A) AT (12 sessions, 4 weeks, high(B) Massage, physical terapy and incuprofen (1 a = 124) prop outPain Drop-outNYun (2012) <sup>12</sup> (216)236 (30%) NS-CLBP (A) NR (41%)(A) AT (12 sessions, 4 weeks, high(B) Massage, physical prop outPain Drop-outNYun (2012) <sup>12</sup> (1 a = 14) (1 m = 20)236 (30%) NS-CLBP (1 m = 20)(A) AT (10 sessions, 5 weeks, high(B) Baclofen (30 mg/day, mediumPain n n = 20)NZaringhalam (2010) <sup>46</sup> (1 ran (2002) <sup>41</sup> 60 (NR) NS-CLBP (A) AT (5 sessions, 5 weeks, nedium(B) Baclofen (30 mg/day, prop-outPain Drop-outNItoh (2009) <sup>50</sup> (1 ran (2002) <sup>44</sup> 66 (57%) NS-CLBP (30 / S-4%)(A) AT (2 sessions, 5 weeks, nedium(B) TEINS (n = 8) Drop-outPain Disability Drop-outNMolsberger (2002) <sup>45</sup> (2002) <sup>44</sup> 66 (47.8%) NS-CLBP (30 / 9, 9, 17%)(A) AT (2 sessions, 4 weeks, ligh(B) Physiotherapy, back, school, mud packs, school, mud packs, school, mud packs, schoo	NR
IndiamediumMathematical and the set of the	
Shankar (2011) <sup>41</sup> 60 (63%) NS-CLBP (A) EA (10sessions, 3 weeks, NR $de qi, n = 30$ ) (B) Valdecoxib (20 mg propout supervised propout) (A) AT (10sessions, 7 weeks, n = 124) (A) AT (18sessions, 7 weeks, n = 124) (A) AT (18sessions, 7 weeks, n = 124) (A) AT (12sessions, 4 weeks, (B) Massage, physical propout) (NS-CLBP (A) AT (12sessions, 4 weeks, (B) Massage, physical propout) (NS-AID) (n = 63) (Drop out) (NS-AID) (n = 63) (NR (A)	
India35,5/1,83 NRNRReq.(i, n = 30) electroacupunctureBD for 10 days) plus supervised physiotherapy (3 weeks)Drop-outYun (2012) China187 (23%) NS-CLBP 40%(A) AT (18 sessions, 7 weeks) medium(B) Massage, physical therapy and medicationsPain DisabilityYun (2012) Yun (2012) 21226 (30%) NS-CLBP 41%(A) AT (12 sessions, 4 weeks, and physical therapy and physical thera	
India35,5/1,83 NRNRR de-qi, $n = 30$ electroacupunctureBD for 10 days) plus supervised physiotherapy (3 weeks)Drop-outYun (2012)*1187 (23%) NS-CLBP(A) AT (10 sessions, 7 weeks)(B) Massage, physical therapy and medicationsPain DisabilityYun (2012)*1226 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, und/%(B) Massage, physical therapy and medicationsPain DisabilityYun (2012)*1226 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, und/%(B) Massage, physical therapy and ibuprofen Disability ( $n = 74$ )Pain Drop-outYun (2010)*1060 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, und/%(B) Baclofen (30 mg/day, $(n = 74)$ Pain Drop-out Drop-out Drop-out Drop-out 24 weeksLebanon54.5/6.9(A) AT (10 sessions, 5 weeks, und(m)(B) AT plus (C) ( $n = 20$ ) $10$ weeks medium(B) TENS ( $n = 8$ ) Drop-out Drop-out Drop-out Drop-out Drop-out Drop-out Drop-out Drop-out Drop-out Drop-outPain NLeibing (2002)*186 (57%) NS-CLBP(A) AT (2 sessions, 12 S2 weeks Iow(B) Active physiotherapy Drop-out Drop-out Drop-outMolsberger (2002)*1186 (47.8%) NS-CLBP 50/9.9(A) AT (2 sessions, 4 weeks, de-qi, $n = 65$ ) plus (B) 17%(B) AT (2 sessions, 4 weeks, de-qi, $n = 65$ ) plus (B) 17%(B) Physiotherapy, back school, mud packs, infrared heat therapy n. 60Pain Y Y Prop-outMolsberger (2002)*1186 (47.8%) NS-CLBP 50/9.9EA (12 sessions, 4 weeks, de-qi, $n = 65$ ) plus (B) 1.9%(B) Exercis	N.D.
NRelectroacupuncture NAsupervised physiotherapy (3 weeks) mediumYun (2012)187 (23%) NS-CLBP(A) AT (18 sessions, 7 weeks, (A) AT (18 sessions, 7 weeks, de-qi, $n = 124$ )(B) Massage, physical (NSAID) ( $n = 63$ )Pain Drop out mediumYun (2012)236 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, (NSAID) ( $n = 63$ )(B) Massage, physical Drop out mediumPain NYun (2012)236 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, ( $n = 74$ )(B) Massage, physical Drop-out 24 weeks high highPain ( $n = 74$ )NZaringhalam (2010)60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, ( $n = 74$ )(B) Baclofen (30 mg/day, Drop-out 24 weeks highPain ( $n = 20$ )NZaringhalam (2010)60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, ( $n = 20$ )(B) Baclofen (30 mg/day, Drop-out Disability Drop-out Dorop-out 10 weeks mediumPain ( $n = 20$ )NItoh (2009)24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, ( $n = 8$ )(B) TENS ( $n = 8$ ) Disability Drop-out DisabilityPain NLeibing (2002)46 ( $57\%$ ) NS-CLBP(A) AT (20sessions, 12 ( $n = 40$ ), plus (B) Toweeks low(B) Active physiotherapy Drop-out DisabilityPain NMolsberger (2002)186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, ( $n = 40$ ), plus (B) T2 weeks medium(B) AT (10 sessions, 5, plus (B) T2 weeks mediumPain NYMolsberger (2002)186 (47.8%) NS-CLBP(A) AT (2sessions, 4 weeks, ( $n = 40$ ), plus (B) T2 weeks medium	NR
NA mediumphysiotherapy (3 weeks) mediumYun (2012) <sup>13</sup> 187 (23%) NS-CLBP (A) AT (18sessions, 7 weeks, 40%(B) Massage, physical therapy and medications (NSAID) ( $n = 63$ )Pain Disability DisabilityYun (2012) <sup>12</sup> 236 (30%) NS-CLBP (A) AT (12 sessions, 4 weeks, (NSAID) ( $n = 63$ )(B) Massage, physical therapy and ibuprofen Disability (NSAID) ( $n = 63$ )Pain N NNYun (2012) <sup>12</sup> 236 (30%) NS-CLBP (A) AT (12 sessions, 4 weeks, (B) Massage, physical and physical therapy 24 weeks(B) Massage, physical therapy and ibuprofen ( $n = 74$ )Pain Disability Drop-outNZaringhalam (2010) <sup>46</sup> (2002) <sup>46</sup> 60 (NR) NS-CLBP (A) AT (10 sessions, 5 weeks, (B) AT plus (C) ( $n = 20$ ) (D) AT plus (C) ( $n = 20$ ) (D) weeks(B) Baclofen (30 mg/day, Disability Disability Disability Disability Drop-outPain NItoh (2009) <sup>59</sup> (2002) <sup>44</sup> (2002) <sup>44</sup> 24 (NR) NS-CLBP (A) AT (20sessions, 5 weeks, (B) AT plus (C) ( $n = 8$ ) (D) NR(B) AT plus (C) ( $n = 8$ ) ( $n = 46$ )Pain Disability Disability Disability Disability Drop-outLeibing (2002) <sup>44</sup> (2002) <sup>44</sup> (2002) <sup>45</sup> 86 (57%) NS-CLBP (A) AT (20sessions, 12 (A) AT (20sessions, 12 (A) AT (20sessions, 4 weeks, de-qi, $n = 63$ ), plus (B) ( $n = 46$ )Pain Disability Disability Disability Drop-out highMolsberger (2002) <sup>45</sup> (2002) <sup>45</sup> 186 (47.8%) NS-CLBP (A) AT (20sessions, 4 weeks, (A) AT (20sessions, 4 weeks, nedium n, 60(B) Physiotherapy point highMolsberger (2002) <sup>45</sup> (D) (9.9) (7%186 (47.8%) NS-CLBP <t< td=""><td></td></t<>	
mediummediumYun (2012)43187 (23%) NS-CLBP(A) AT (18sessions, 7 weeks, (NSALD) ( $n = 63$ )PainNChina34/NR $d-e_{i}, n = 124$ )therapy and medicationsDisability40%48 weeks(NSALD) ( $n = 63$ )Drop outmedium(A) AT (12 sessions, 4 weeks, (A) AT (12 sessions, 4 weeks, (a) AT (12 sessions, 4 weeks, (a) AT (12 sessions, 5 weeks, (a) AT (10 sessions, 5 weeks, (b) AT plus (C) ( $n = 20$ )PainNZaringhalam (2010)4860 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, (A) AT (10 sessions, 5 weeks, (B) AT plus (C) ( $n = 20$ )(B) Baclofen (30 mg/day, Drop-outPainNZaringhalam (2010)4860 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, (A) AT (10 sessions, 5 weeks, (B) AT plus (C) ( $n = 20$ )(B) Baclofen (30 mg/day, Drop-outPainNItaa54.5/6.9(A) AT (10 sessions, 5 weeks, (B) AT plus (C) ( $n = 8$ )(B) TENS ( $n = 8$ )PainNItaa74.5/6.9(A) AT (5 sessions, 5 weeks, (A) AT (20 sessions, 12(B) Attrie physiotherapy Drop-outDrop-outItaa74.5/6.9(A) AT (20 sessions, 12(B) Attrie physiotherapy ( $n = 46$ )PainNItaa96 (57%) NS-CLBP(A) AT (12 sessions, 4 weeks, (A) AT (12 sessions, 4 weeks, ( $n = 46$ )PainYGermany50/9.916 (47.8%) NS-CLBP(A) AT (12 sessions, 4 weeks, ( $A AT (12 sessions, 4 weeks,(A AT (12 sessions, 4 weeks,(A AT (12 sessions, 4 weeks,(A AT (12 ses$	
Yun (2012)13187 (23%) NS-CLEP(A) AT (18sessions, 7 weeks, de-qi, $n = 124$ )(B) Massage, physical therapy and medications Disability Disability Disability mediumPainNYun (2012)12236 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, medium(B) Massage, physical (NSAID) $(n = 63)$ PainNYun (2012)12236 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, and physical therapy 24 weeks high(B) Massage, physical (n = 162), plus massage therapy and ibuprofen (n = 74)Pain Disability Drop-outNZaringhalam (2010)4860 (NR) NS-CLBP 54.5/6.9(A) AT (10 sessions, 5 weeks, (B) AT (10 sessions, 5 weeks, medium(B) Baclofen (30 mg/day, n = 20)Pain Disability Drop-outNItoh (2009)5924 (NR) NS-CLBP (A) AT (10 sessions, 5 weeks, medium(B) TENS (n = 8) (B) AT plus (C) (n = 20) Drop-outPain NNItoh (2009)5924 (NR) NS-CLBP (A) AT (20 sessions, 5 weeks, (B) AT, plus (C) (n = 8) 10 weeks low(B) AT, plus (C) (n = 8) Drop-outPain NNIde-qi, n = 80 (B) AT, plus (C) (n = 8) 10 weeks low86 (57%) NS-CLBP(A) AT (20 sessions, 12 Weeks, n = 40), plus (B) S 20 weeks S 20 weeks(B) Active physiotherapy DisabilityPain Drop-outYMolsberger (2002)4586 (47.8%) NS-CLBP(A) AT (12 sessions, 4 weeks, medium(B) Physiotherapy, back school, mud packs, infrared heat therapy n. 60Pain Drop-outYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise (n = 26) Dr	
China34/NR 40%de-qi, $n = 124$ therapy and medications (NSALD) $(n = 63)$ Disability Drop out mediumYun (2012) <sup>12</sup> 236 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, and physical therapy 24 weeks(B) Massage, physical ( $n = 74$ )Pain Drop-outNLebanon33/NR de-qi, $n = 162$ ), plus massage and physical therapy 24 weeks(B) Baclofen (30 mg/day, $n = 20$ )Pain DisabilityNZaringhalam (2010) <sup>48</sup> fram60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, high(B) Baclofen (30 mg/day, $n = 20$ )Pain DisabilityNZaringhalam (2010) <sup>48</sup> fram60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, medium(B) Baclofen (30 mg/day, $n = 20$ )Pain DisabilityItran54.5/6.9(B) AT plus (C) ( $n = 20$ ) 10 weeks medium $n = 20$ Disability DisabilityItoh (2009) <sup>59</sup> Japan24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, (B) AT, plus (C) ( $n = 8$ ) 10 weeks lowPain NNLeibing (2002) <sup>44</sup> Germany86 (57%) NS-CLBP(A) AT (12 sessions, 12 186 (47.8%) NS-CLBP(A) AT (12 sessions, 12 12 weeks, $n = 40$ ), plus (B) 12 weeks medium(B) Physiotherapy school, mud packs, infrared heat therapy $n, 60$ Pain Drop-outYYeung (2003) <sup>46</sup> Hong Kong52 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise ( $n = 26$ ) PainPain Drop-outYYeung (2003) <sup>46</sup> Hong Kong52 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise ( $n = 26$ ) Pain Drop-outPain Pa	NR
	1111
Mark PainMark (A) AT (12 sessions, 4 weeks, (a) A (10 sessions, 5 weeks, (b) Baclofen (30 mg/day, (a) A (10 sessions, 5 weeks, (b) Baclofen (30 mg/day, (a) A (10 sessions, 5 weeks, (b) Baclofen (30 mg/day, (a) AT (10 sessions, 5 weeks, (b) Baclofen (30 mg/day, (b) A (10 sessions, 5 weeks, (b) Baclofen (30 mg/day, (b) Baclofen (30 mg/day, (b) <b< td=""><td></td></b<>	
Yun (2012)236 (30%) NS-CLBP(A) AT (12 sessions, 4 weeks, de-qi, $n = 162$ ), plus masage therapy and ibuprofen $24$ weeks highPain therapy and ibuprofen Disability $24$ weeks highNZaringhalam (2010)60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, high(B) Baclofen (30 mg/day, $n = 20$ ) DisabilityPain NNZaringhalam (2010)60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, medium(B) Eaclofen (30 mg/day, $n = 20$ ) DisabilityPain NNItoh (2009)9324 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, medium(B) TENS ( $n = 8$ ) Drop-outPain DisabilityNItoh (2009)24 (NR) NS-CLBP(A) AT (20 sessions, 5 weeks, medium(B) TENS ( $n = 8$ ) Drop-outPain DisabilityNItoh (2009)24 (NR) NS-CLBP(A) AT (20 sessions, 5 weeks, medium(B) AT, plus (C) ( $n = 8$ ) Drop-outPain DisabilityNLeibing (2002)46 (57%) NS-CLBP(A) AT (20 sessions, 12 U weeks Drop-out(B) Active physiotherapy StabilityPain Drop-outYMolsberger (2002)186 (47.8%) NS-CLBP(A) AT (12 sessions, 4 weeks, Igh(B) Physiotherapy, back Stop, po- DisabilityPain Drop-outYYeung (2003)52 (82%) NS-CLBPEA (12 sessions, 4 weeks, If%(B) Physiotherapy, back Stop, po- DisabilityPain Drop-outYYeung (2003)52 (82%) NS-CLBPEA (12 sessions, 4 weeks, If%(B) Exercise ( $n = 26$ ) PainPain Pain PainYYeung (2003)52 (82%) N	
Lebanon33/NR $41\%$ de-qi, $n = 162$ ), plus massage and physical therapy $(n = 74)$ Disability Drop-out $24$ weeks highand physical therapy $(n = 74)$ Drop-outZaringhalam (2010) <sup>48</sup> 60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, de-qi, $n = 20$ )(B) Baclofen (30 mg/day, $n = 20$ )PainNIran54.5/6.9(B) AT plus (C) ( $n = 20$ ) $10$ weeks medium $n = 20$ Disability Drop-outDisability $10$ weeks mediumItoh (2009) <sup>59</sup> 24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, medium(B) TENS ( $n = 8$ )PainNItoh (2009) <sup>59</sup> 24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, medium(B) TENS ( $n = 8$ )PainNItoh (2009) <sup>59</sup> 24 (NR) NS-CLBP(A) AT (2 sessions, 12 to weeks low(B) Active physiotherapy DisabilityPainYLeibing (2002) <sup>44</sup> 86 (57%) NS-CLBP(A) AT (2 sessions, 12 to weeks low(B) Active physiotherapy Drop-outPainYMolsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP(A) AT (12 sessions, 4 weeks, nfard heat therapy medium(B) Physiotherapy, back school, mud packs, infrared heat therapy mediumPain n GoYYeung (2003) <sup>46</sup> 52 (82%) NS-CLEPEA (12 sessions, 4 weeks, nedium(B) Exercise ( $n = 26$ ) Drop-outPain PainYYeung (2003) <sup>46</sup> 52 (82%) NS-CLEPEA (12 sessions, 4 weeks, nfared heat therapy nedium(B) Exercise ( $n = 26$ ) PainPain PainYYeung (2003) <sup>46</sup> 1.9%1.2 weeks medium <td< td=""><td>NR</td></td<>	NR
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
Zaringhalam (2010)60 (NR) NS-CLBP(A) AT (10 sessions, 5 weeks, (B) Baclofen (30 mg/day, (B) AT (10 sessions, 5 weeks, (B) TENS ( $n = 20$ )Disability Drop-out Drop-out I0 weeks mediumItoh (2009)24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, (B) TENS ( $n = 8$ )PainNItoh (2009)24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, (B) AT, plus (C) ( $n = 8$ )(B) TENS ( $n = 8$ )PainNJapanrange :61-81/NR NRde-qi, $n = 8$ ) (B) AT, plus (C) ( $n = 8$ )Drop-outDisabilityDrop-outI0 weeks low10 weeks low10 weeks lowDrop-outDisabilityDrop-outGermany47.7/9.6 54%52 weeks highMathematical State ( $n = 46$ )DisabilityDrop-outMolsberger (2002)186 (47.8%) NS-CLBP(A) AT (12 sessions, 4 weeks, medium(B) Physiotherapy, back school, mud packs, infrared heat therapy n. 60Pain VYYeung (2003)52 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise ( $n = 26$ )Pain Pain Pain VYYeung (2003)52 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise ( $n = 26$ )Pain Pain Pain Pain PainYYeung (2003)52 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise ( $n = 26$ )Pain Pain Pain PainYYeung (2003)52 (82%) NS-CLBP	
Zaringhalam (2010)4860 (NR) NS-CLBP(Å) AT (10 sessions, 5 weeks, (B) Baclofen (30 mg/day, $n = 20$ )PainNIran54.5/6.9de-qi, $n = 20$ ) $n = 20$ )Disability Drop-outNR(B) AT plus (C) $(n = 20)$ $n = 20$ )Drop-out10 weeks mediumned-qi, $n = 8$ )PainNItoh (2009)3924 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, medium(B) TENS $(n = 8)$ PainNItoh (2009)4486 (57%) NS-CLBP(A) AT (2 sessions, 12(B) Active physiotherapy IowPainYLeibing (2002)4486 (57%) NS-CLBP(A) AT (2 sessions, 12(B) Active physiotherapy IowPainYGermany47.7/9.6weeks subwitDrop-outDisability Drop-outDrop-outMolsberger (2002)45186 (47.8%) NS-CLBP(A) AT (12 sessions, 4 weeks, nedium(B) Physiotherapy, back school, mud packs, infrared heat therapy nediumPainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise $(n = 26)$ PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise $(n = 26)$ PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise $(n = 26)$ PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise $(n = 26)$ PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise $(n = 26)$ P	
fran54.5/6.9de-qi, $n = 20$ $n = 20$ DisabilityNR(B) AT plus (C) $(n = 20)$ Drop-outDrop-out10 weeksmediumttoh (2009) <sup>39</sup> 24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, medium(B) TENS $(n = 8)$ PainNJapanrange :61-81/NR NRde-qi, $n = 8$ Disability Drop-outDrop-outNLeibing (2002) <sup>44</sup> 86 (57%) NS-CLBP(A) AT (20sessions, 12 low(B) Active physiotherapy Drop-outPain DisabilityLeibing (2002) <sup>44</sup> 86 (57%) NS-CLBP(A) AT (20sessions, 12 low(B) Active physiotherapy Drop-outPain DisabilityMolsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, nfgh(B) Physiotherapy, back school, mud packs, infrared heat therapy n. 60Pain Pai	
NR(B) AT plus (C) $(n = 20)$ 10 weeks mediumDrop-outItoh (2009) <sup>39</sup> 24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, (B) TENS $(n = 8)$ (B) AT, plus (C) $(n = 8)$ NRPainNJapanrange :61-81/NR NRde-qi, $n = 8$ ) (B) AT, plus (C) $(n = 8)$ lowDisability Drop-outDrop-outLeibing (2002) <sup>44</sup> 86 (57%) NS-CLBP(A) AT (20sessions, 12 uweeks, $n = 40$ ), plus (B) S2 weeks(B) Active physiotherapy Drop-outPain PainYGermany47.7/9.6 54%S2 weeks high(B) Physiotherapy, back school, mud packs, infrared heat therapy nediumPain Pain	NR
10 weeks medium10 weeks mediumItoh (2009)3924 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, (B) TENS $(n = 8)$ PainNJapanrange :61-81/NR(B) AT, plus (C) $(n = 8)$ DisabilityDrop-outNR(B) AT, plus (C) $(n = 8)$ Drop-outDrop-out10 weekslowIowIowIowLeibing (2002)4486 (57%) NS-CLBP(A) AT (20sessions, 12(B) Active physiotherapyPainYGermany47.7/9.6yeeks, $n = 40$ , plus (B) $(n = 46)$ DisabilityYMolsberger (2002)45186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, ned-qi, $n = 65$ ), plus (B)school, mud packs, infrared heat therapyPainYGermany52 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise ( $n = 26$ )PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise ( $n = 26$ )PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise ( $n = 26$ )PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise ( $n = 26$ )PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise ( $n = 26$ )PainYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, mediumDrop-outDrop-outYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, medium(B) Exercise ( $n = 26$ )PainY <t< td=""><td></td></t<>	
Itoh (2009) Japan24 (NR) NS-CLBPmedium (A) AT (5 sessions, 5 weeks, (B) TENS $(n = 8)$ Pain NNJapanrange :61-81/NR NRde-qi, $n = 8$ ) (B) AT, plus (C) $(n = 8)$ lowDisability Drop-outDisability Drop-outNLeibing (2002) Germany86 (57%) NS-CLBP(A) AT (20sessions, 12 S4%(B) Active physiotherapy DisabilityPain PAInYMolsberger (2002) Germany186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, 12 weeks 12 weeks(B) Physiotherapy, back school, mud packs, infrared heat therapy n. 60Pain YYYeung (2003) 4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, 4c-qi, $n = 26$ ), plus (B) 12 weeks medium(B) Exercise ( $n = 26$ ) PainPain YYYeung (2003) 4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, 4c-qi, $n = 26$ ), plus (B) 12 weeks medium(B) Exercise ( $n = 26$ ) Poro-outPain YYYeung (2003) 4653/NR 12 weeks medium12 weeks medium(B) Exercise ( $n = 26$ ) Poro-outPain Poro-outY	
Itoh (2009)24 (NR) NS-CLBP(A) AT (5 sessions, 5 weeks, (B) TENS ( $n = 8$ )PainNJapanrange :61-81/NR NRde-qi, $n = 8$ ) (B) AT, plus (C) ( $n = 8$ ) lowDisability Drop-outDisability Drop-outLeibing (2002)86 (57%) NS-CLBP(A) AT (20sessions, 12 (A) AT (20sessions, 12(B) Active physiotherapy DisabilityPain PainYGermany47.7/9.6 54%weeks, $n = 40$ ), plus (B) ( $n = 46$ )( $n = 46$ )Disability Drop-outPain PainYMolsberger (2002)186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, nequin(B) Physiotherapy, back nfrared heat therapy n. 60Pain YYYeung (2003)52 (82%) NS-CLBPEA (12 sessions, 4 weeks, nedium(B) Exercise ( $n = 26$ ) Drop-outPain YYYeung (2003)52 (82%) NS-CLBPEA (12 sessions, 4 weeks, nfrared heat therapy nedium(B) Exercise ( $n = 26$ ) Drop-outPain YYYeung (2003)52 (82%) NS-CLBPEA (12 sessions, 4 weeks, nfrared heat therapy nedium(B) Exercise ( $n = 26$ ) Drop-outPain YYYeung (2003)53/NR 1.9%12 weeks medium(B) Exercise ( $n = 26$ ) Drop-outPain YY	
Japanrange :61-81/NR NRde-qi, $n = 8$ )DisabilityNR(B) AT, plus (C) $(n = 8)$ 10 weeks lowDrop-outLeibing (2002) <sup>44</sup> 86 (57%) NS-CLBP(A) AT (20sessions, 12 92 (B) Active physiotherapyPain DisabilityGermany47.7/9.6 54%52 weeks, $n = 40$ ), plus (B) $(n = 46)$ Disability DisabilityMolsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, 16gh(B) Physiotherapy, back Drop-outPain Pain PainY Pain Pain Pain Pain Pain Pain PainMolsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, 17%(B) Physiotherapy, back prop-outPain <b< td=""><td></td></b<>	
NR(B) AT, plus (C) $(n = 8)$ 10 weeks lowDrop-outLeibing (2002) <sup>44</sup> 86 (57%) NS-CLBP(A) AT (20sessions, 12(B) Active physiotherapy DisabilityPain DisabilityGermany47.7/9.6 54%weeks, $n = 40$ ), plus (B) $54\%$ $(n = 46)$ DisabilityDisability Drop-outMolsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, $150/9.9$ $17\%$ (B) Physiotherapy, back de-qi, $n = 65$ ), plus (B) $12$ weeksPain prop-outY Pain P	NR
Leibing (2002) <sup>44</sup> 86 (57%) NS-CLBP(A) AT (20sessions, 12(B) Active physiotherapyPainYGermany $47.7/9.6$ weeks, $n = 40$ ), plus (B) $(n = 46)$ Disability54%52 weeksDrop-outMolsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, tigh(B) Physiotherapy, backPainYMolsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, tigh(B) Physiotherapy, backPainYGermany50/9.9de-qi, $n = 65$ ), plus (B)school, mud packs, infrared heat therapyDrop-out17%12 weeksinfrared heat therapyDrop-outYeung (2003) <sup>46</sup> 52 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ )PainYHong Kong53/NR 1.9%12 weeks mediumDrop-outTop-outY	
Leibing (2002) <sup>44</sup> Bé (57%) NS-CLBP Germany 47.7/9.6 54% Molsberger (2002) <sup>45</sup> Germany 186 (47.8%) NS-CLBP Germany 50/9.9 17% 186 (47.8%) NS-CLBP 6-qi, n = 65), plus (B) $12 weeks12 weeks12 weeks12 weeks12 weeks12 weeks1.60EA (12 sessions, 4 weeks, (B) Physiotherapy, back 12 weeks16 e-qi, n = 65), plus (B) 12 weeks12 weeks16 e-qi, n = 26), plus (B) 1.9%12 weeks12 wee$	
Leibing (2002) 486 (57%) NS-CLBP(A) AT (20sessions, 12 weeks, $n = 40$ ), plus (B)(B) Active physiotherapy Disability Drop-outGermany47.7/9.6 54%52 weeks high( $n = 46$ )Disability Drop-outMolsberger (2002) 45186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, de-qi, $n = 65$ ), plus (B)(B) Physiotherapy, back school, mud packs, infrared heat therapy mediumPain YYeung (2003) 4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ ) Drop-outPain YYeung (2003) 4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ ) Drop-outPain YYeung (2003) 4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ ) Drop-outPain YYeung (2003) 4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ ) Drop-outPain Y	
Germany47.7/9.6weeks, $n = 40$ ), plus (B) $(n = 46)$ Disability54%52 weeksDrop-outMolsberger (2002)45186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, de-qi, $n = 65$ ), plus (B)(B) Physiotherapy, back school, mud packs, infrared heat therapy mediumPain Drop-outYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ )Pain Drop-outYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, 1.9%(B) Exercise ( $n = 26$ )Pain Drop-outYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, 1.2 weeks medium(B) Exercise ( $n = 26$ )Pain Drop-outY	Yes
54%52 weeks highDrop-out highMolsberger (2002)45186 (47.8%) NS-CLBP(A) AT (12sessions, 4 weeks, de-qi, $n = 65$ ), plus (B)(B) Physiotherapy, back school, mud packs, infrared heat therapy mediumPain Drop-outYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ )Pain Drop-outYYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ )Pain Drop-outYYoung (2003)4653/NR 1.9%12 weeks mediumDrop-outY	105
high Molsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP Germany 50/9.9 17% 12 weeks (B) Physiotherapy, back Pain Y de-qi, n = 65), plus (B) school, mud packs, Drop-out 12 weeks infrared heat therapy medium n. 60 Yeung (2003) <sup>46</sup> 52 (82%) NS-CLBP EA (12 sessions, 4 weeks, (B) Exercise (n = 26) Pain Y Hong Kong 53/NR de-qi, n = 26), plus (B) Drop-out 1.9% 12 weeks medium	
Molsberger (2002) <sup>45</sup> 186 (47.8%) NS-CLBP       (Å) AT (12sessions, 4 weeks, (B) Physiotherapy, back Pain Y         Germany       50/9.9       de-qi, n = 65), plus (B)       school, mud packs, Drop-out         17%       12 weeks       infrared heat therapy         reduim       n. 60         Yeung (2003) <sup>46</sup> 52 (82%) NS-CLBP       EA (12 sessions, 4 weeks, (B) Exercise (n = 26)       Pain Y         Hong Kong       53/NR       de-qi, n = 26), plus (B)       Drop-out       Drop-out         1.9%       12 weeks       medium       Drop-out       Y	
Germany50/9.9 17%de-qi, $n = 65$ ), plus (B) 12 weeks mediumschool, mud packs, infrared heat therapy n. 60Drop-outYeung (2003)4652 (82%) NS-CLBPEA (12 sessions, 4 weeks, de-qi, $n = 26$ ), plus (B)(B) Exercise ( $n = 26$ )Pain Drop-outYHong Kong53/NR 1.9%de-qi, $n = 26$ ), plus (B)Drop-outY	Yes
17%     12 weeks     infrared heat therapy       Yeung (2003) <sup>46</sup> 52 (82%) NS-CLBP     EA (12 sessions, 4 weeks, (B) Exercise (n = 26)       Hong Kong     53/NR     de-qi, n = 26), plus (B)     Drop-out       1.9%     12 weeks     medium	100
Yeung $(2003)^{46}$ 52 $(82\%)$ NS-CLBPEA $(12 \text{ sessions}, 4 \text{ weeks}, (B) \text{ Exercise } (n = 26)$ PainYHong Kong53/NRde-qi, $n = 26$ ), plus (B)Drop-out1.9%12 weeksmedium	
Hong Kong         53/NR         de-qi, n = 26), plus (B)         Drop-out           1.9%         12 weeks         medium	
Hong Kong         53/NR         de-qi, n = 26), plus (B)         Drop-out           1.9%         12 weeks         medium	
1.9% 12 weeks medium	Yes
medium	
$M_{ODG}$ (2002)4/ EE (ND) NC CI DD AT (10 ansains E supplies (D) NC AIDs much Delta D	
	Yes
USA 71/NR de-qi, $n = 31$ ), plus (B) relaxants, paracetamol Disability	
71%9 weeksand back exercisesDrop-outhigh $(n = 24)$	

AT: acupuncture treatment; EA: electro acupuncture; NA: not applicable; NR: not reported; NSAID: non-steroidal anti-inflammatory drug; NS-CLBP: non-specific chronic low back pain; TENS: transcutaneous electrical nerve stimulation.




Fig. 2. Risk of bias summary: Review authors' judgments of bias items for each included study.

#### 3.4. Effects of interventions

#### 3.4.1. Acupuncture alone

3.4.1.1. Acupuncture versus non-pharmacologic treatment. We didn't find any significant difference in pain measured by visual analogue scale (VAS) (MD 0.10, 95%CI –15.05 to 15.25; 3 studies, 141 participants, low certainty of evidence), disability (SMD 0.19 95%CI –0.06 to 0.44; 3 studies, 256 participants, low certainty of evidence), drop out from treatment (RR 1.56, 95%CI 0.43 to 5.61; 4 studies, 316 participants, low certainty of evidence). None of the studies reported the number of subjects with at least one adverse event (Table 2; Figure 3 in the Supplementary material).

We didn't find any significant difference for quality of life (MD -4.20, 95%CI -10.11 to 1.71; 1 study, 68 participants), subjects using analgesics (RR 1.08, 95%CI 0.79 to 1.46; 1 study, 172 participants), while the mean use of drugs in the last week of treatment decreased with acupuncture (MD -13.00, 95%CI -25.63 to -0.37; 1 study, 60 participants).

3.4.1.2. Acupuncture versus pharmacologic treatment. We didn't find any significant difference in pain measured by visual analogue scale (VAS) (MD -2.17, 95%CI -12.69 to 8.35; 3 studies, 347 participants, low certainty of evidence), disability (SMD -0.44 95%CI -1.22 to 0.34; 3 studies, 347 participants, very low certainty of evidence); there were only 1 participant who dropped out from treatment in each arm in one study<sup>47</sup> in both arms (RR 1.00 [95%CI 0.07 to 14.90] 3 studies, 347 participants, very low certainty of evidence). None of the studies reported the number of subjects with at least one adverse event (Table 2; Figure 4 in the Supplementary material).

We didn't find any significant difference for quality of life (MD 0.20, 95%CI –5.82 to 6.22; 1 study, 71 participants).

3.4.1.3. Acupuncture versus combined pharmacological and nonpharmacological treatment. Pain was reduced with acupuncture (SMD -0.50, 95%CI -0.62 to -0.37; 3 studies, 1022 participants, moderate certainty of evidence); disability was reduced with acupuncture (SMD -0.71, 95%CI -1.17 to -0.24; 3 studies, 1438 participants, low certainty of evidence); we didn't find difference in dropout rate (RR 0.64, 95%CI 0.41 to 1.02; 4 studies, 1498 participants, low certainty of evidence). None of the studies reported the number of subjects with at least one adverse event (Table 2; Figure 5 in the Supplementary material).

#### 3.4.2. Acupuncture as add-on to conventional treatment

3.4.2.1. Acupuncture in addition to non-pharmacological treatment versus non-pharmacological treatment alone. Pain was reduced with acupuncture (SMD -0.70, 95%CI -0.94 to -0.46; 4 studies, 279 participants, very low certainty of evidence); disability was reduced with acupuncture (SMD -0.95, 95%CI -1.36 to -0.54; 2 studies, 1028 participants, very low certainty of evidence); we didn't find difference in dropout rate (RR 1.24, 95%CI 0.54 to 2.81; 4 studies, 279 participants, very low certainty of evidence). None of the studies reported the number of subjects with at least one adverse event (Table 2; Figure 6 in the Supplementary material).

We didn't find any significant difference in subjects using analgesics (RR 3.00, 95%CI 0.67 to 13.51; 1 study 52 participants), while we found an improvement in functional state measured by Aberdeen LBP scale (MD -10.80, 95%CI -17.22 to -4.38; 1 study, 52 participants).

3.4.2.2. Acupuncture in addition to pharmacological treatment versus pharmacological treatment alone. Pain was reduced with acupuncture (MD: -21.80, 95%CI -33.18 to -10.42, 1 study, 40 participants low certainty of evidence); disability (Roland Disability Questionnaire) was reduced with acupuncture (MD -3.10, 95%CI -4.87 to -1.83; 1 study, 40 participants, low certainty of evidence. One patient dropped out from treatment in each arm (RR: 1.00, 95%CI 0.07 to 14.90, 1 study, 40 participants)

#### Table 2

Summary of results.

Acupuncture alone vs. non-pharmacological treatment						
		No. of studies				
Outcome	Result	(participants)	Certainty of Evidence	Favors		
Pain	MD 0.10 (95% CI -15.05 to 15.25)	3 (141)	LOW	=		
Disability	MD 0.19 (95% CI -0.06 to 0.44)	3 (256)	LOW	=		
Drop out	RR 1.56 (95% CI 0.43 to 5.61)	4 (316)	LOW	=		
Quality of Life	MD -4.20 (95% CI -10.11 to 7.17)	1 (68)	VERY LOW	=		
Analgesics use	RR 1.08 (95% CI 0.79 to 1.46)	1 (172)	VERY LOW	=		
Use of drug (last week of treatment)	MD -13.00 (95% CI -25.63 to 0.37)	1 (60)	VERY LOW	=		
Acupuncture alone vs. pharmacologic	al treatment					
Pain	MD -2.17(95%CI -12.69 to 8.35)	3 (347)	LOW	=		
Disability	MD -0.44 (95% CI -1.22 to 0.34)	3 (347)	VERY LOW	=		
Drop out	RR 1.00 (95%CI 0.07 to 14.90)	3 (347)	VERY LOW	=		
Quality of Life	MD 0.20 (95% CI -5.82 to 6.22)	1 (71)	VERY LOW	=		
Acupuncture alone vs. combined phan	macological & non-pharmacological treatment					
Pain	SMD -0.50 (95% CI -0.62 to -0.37)	3 (1022)	MODERATE	+		
Disability	SMD -0.71 (95% CI -1.17 to -0.24)	3 (1438)	LOW	+		
Drop out	RR 0.64 (95% CI 0.41 to 1.02)	4 (1498)	LOW	=		
Acupuncture + non-pharmacological	treatment vs. non-pharmacological treatment					
Pain	SMD -0.70 (95% CI -0.94 to -0.46)	4 (279)	VERY LOW	+		
Disability	SMD -0.95 (95% CI -1.36 to -0.54)	2 (1028)	VERY LOW	+		
Drop out	RR 1.24 (95% CI 0.54 to 2.81)	4 (279)	VERY LOW	=		
Analgesics use	RR 3.00 (95% CI 0.67 to 13.51)	1 (52)	VERY LOW	=		
Functional status	MD -10.80 (95% CI -17.22 to -4.38)	1 (52)	VERY LOW	+		
Acupuncture + pharmacological & no	n-pharmacological treatment vs. pharmacologica	al & non-pharmacological tr	eatment			
Pain	MD -0.60 (95% CI -1.22 to 0.02)	1 (55)	VERY LOW	=		
Disability	MD -3.40 (95% CI -5.17 to -1.63)	1 (55)	VERY LOW	+		
Drop out	RR 5.42 (95% CI 0.71 to 41.11)	1 (55)	VERY LOW	=		
Analgesics use	RR 0.88 (95% CI 0.73 to 1.04)	1 (52)	VERY LOW	=		
Acupuncture + pharmacological treat	ment vs. pharmacological treatment					
Pain	MD -21.80 (95%CI -33.18 to -10.42)	1 (40)	LOW	+		
Disability	MD -3.10 (95%CI -4.87 to -1.83)	1 (40)	LOW	+		
Drop out	RR 1.00 (95%CI 0.07 to 14.90)	1 (40)	VERY LOW	=		

= No statistically different; + Favors acupuncture alone or in combination with other treatments.

pants, very low certainty of evidence) (Table 2; Figure 7 in the Supplementary material).

3.4.2.3. Acupuncture in addition to combined pharmacological and nonpharmacological treatment versus combined pharmacological and nonpharmacological treatment alone. We didn't find any significant difference in pain measured by visual analogue scale (VAS) (MD -0.60, 95%CI -1.22 to 0.02; 1 study, 55 participants, very low certainty of evidence), while disability was reduced with acupuncture (MD -3.40 95%CI -5.17 to -1.63; 1 study, 55 participants, very low certainty of evidence); we didn't find difference in dropout rate (RR 5.42, 95%CI 0.71 to 41.11; 1 study, 55 participants, very low certainty of evidence). None of the studies reported the number of subjects with at least one adverse event (Table 2; Figure 8 in the Supplementary material).

We didn't find any significant difference in subjects using analgesics (RR 0.88, 95%CI 0.73 to 1.04; 1 study 55 participants).

Certainty of evidence ranged from moderate to very low (Table 2 in the Supplementary material).

#### 4. Discussion

We found no difference in pain or disability with low or very low certainty evidence when acupuncture was compared to non-pharmacologic or pharmacological treatment. When compared to combined pharmacological and non-pharmacological treatment, we found moderate certainty evidence that acupuncture reduced pain and low-quality evidence that it reduced disability. When acupuncture was prescribed as add-on to non-pharmacological treatment, we found that acupuncture was efficacious in reducing pain and disability, but the certainty of evidence was very low. Finally, when acupuncture was prescribed as add-on to combined pharmacological and non-pharmacological treatment, we found no difference in reducing pain, but an improvement in disability, with very low certainty evidence.

When we defined our inclusion criteria, we decided to not use the term "usual care" for the definition of the comparison interventions, as under the broad and vague term "usual care" authors could consider any kind of treatment which is very often not described in the studies. This lack of description could limit the applicability of the results in clinical practice as clinicians could not understand with what acupuncture was actually compared. Therefore, we grouped the studies for the type of comparison intervention, namely pharmacological treatment, nonpharmacological treatment, and combined pharmacological and nonpharmacological treatment. Furthermore, we distinguished the studies that assessed the efficacy of acupuncture given as an alternative to conventional treatment for the studies that used acupuncture as an additional treatment.

For this reason, we excluded trials that simply defined the comparison intervention as "usual care" and, although the total number of finally included studies was not small, we were able to pool a small number of studies in each comparison as the retrieved studies used a large variety of comparison interventions. This could explain, at least partially, the lack of significant results, as the sample size were small and results largely imprecise.

After applying the concept of dose of acupuncture,<sup>29</sup> we tried to standardize treatment by considering the three most important parameters involved to provide effective treatment: number of points needled during each session, de qi response, and number of treatment sessions. By setting these parameters, we were able to introduce the concept of doseintensity with the aim to reduce heterogeneity among studies. However, while this subgroup analysis yielded informative results in other setting,<sup>30</sup> we were unable to find significant differences among studies, probably because of due to the small number of studies that we able to include in each comparison.

Studies using sham and placebo acupuncture as control groups were not included in our review, since they are not suitable comparators.<sup>55</sup>

According to the widely recognized principle that no skin stimulation is inert, "sham acupuncture" cannot be inert since any skin stimulation brings about central and peripheral responses<sup>56</sup> and the same applies to whatever form of placebo acupuncture involving skin stimulation. A light touch of the skin stimulates mechanoreceptors coupled to slow conducting unmyelinated (C) afferents; activity in these afferents has been suggested to induce a "limbic touch" response resulting in emotional and hormonal reactions. Control procedures which are meant to be inert are likely to activate these afferents.<sup>57</sup> In conclusion, comparison of verum acupuncture vs sham or placebo acupuncture may unnecessarily confuse rather than clarify the interpretation of the effects: that is why they were both excluded from our study. More positive and reliable outcomes from the administration of acupuncture can be expected if acupuncture is compared only with usual care.<sup>58</sup>

The most relevant flaws of the included studies were the high risk of performance and detection bias due to lack of blinding in all the studies, though it should be noted that both performance and detection bias are unavoidable for the types of intervention compared; the risk of bias is further increased by the subjective nature of the outcomes assessed. Overall, the certainty of evidence was judged as low or very low according to the GRADE approach for most primary outcomes due to risk of bias and imprecision in the estimate, as few and heterogeneous studies with different comparison interventions and small sample size were included in each comparison.

However, in the comparisons where the sample size was adequate, the clinically meaningful role played by acupuncture emerged more clearly and outcomes revealed a tendency to confirm the effectiveness of acupuncture.

Our results are not directly comparable with the results of a recent Cochrane review<sup>4</sup> as the inclusion criteria and the comparisons were different; nevertheless, the overall conclusions reached by Mu 2020 were consistent with our findings.

Our review relies on a comprehensive bibliographic search on several databases without time restriction and in the rigor of the methodology that followed the highest standards as recommended by Cochrane.<sup>23</sup>

However, our review has some limitations. The lack of information about adverse effects experienced by participants in the primary studies prevented us from comparing safety data, particularly relevant for the comparison with pharmacologic treatments. However, the adverse effects of drugs usually prescribed for CLBP are well known, especially in the long term<sup>59-61</sup>; and information about safety of acupuncture could be drawn from indirect evidence.<sup>62</sup>

We limited our inclusion criteria to studies published in western languages due to our inability to translate studies published in Chinese or other eastern languages. Given the widespread use of acupuncture in Eastern countries and particularly in China, we probably missed some studies that made our comparison of interest. Furthermore, we were unable to visually inspect funnel plot for the presence of possible publication bias because if fewer than 10 studies are included in meta-analyses, the funnel plot is considered uninformative.<sup>24</sup>

On the basis of the results of this systematic review, we are uncertain whether acupuncture as either an alternative or add-on treatment to conventional therapy is more effective and safer than conventional therapy. However, in the comparison with large sample size without imprecision of the estimates, the clinically meaningful role played by acupuncture emerged more clearly and outcomes revealed a tendency to confirm its effectiveness. Acupuncture could be a viable option based on patients' underlying disorders, costs, availability, and preferences. Further randomized trials should be conducted with large sample sizes and a detailed description of the comparison intervention.

#### Author contributions

CMG, MGB and MGL conceptualized and designed the study. MGL and CMG screened studies from title and abstract, extracted data from included studies, assesses risk of bias, undertook data analysis, evaluated the certainty of evidence, and drafted the initial manuscript. MGL performed search strategies, screened studies from title and abstract, extracted data from included studies and drafted supplementary material. CMG, AP, MGB, and EM wrote the introduction and the discussion. All review authors contributed to writing and revising the final manuscript.

#### **Conflicts of interest**

CMG is an editorial board member of the journal. However, his membership had no bearing on the review process or decision. The authors declare no other conflicts of interest.

#### Funding

This research was supported by the Italian Federation of Acupuncture Societies, Bologna, Italy (FISA).

#### **Ethical statement**

Not applicable.

#### Data availability

The data that support the findings of this study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

#### Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.imr.2023.100972.

- Supplement 1. Search strategy
- Supplement 2. Excluded studies and reasons for exclusion
- Supplement 3. Summary of findings results.
- Supplement 4. Supplementary figures
- Supplement 5. PRISMA 2020 Checklist

#### References

- Balagué F, Mannion AF, Pellisé F, Cedraschi C. Non-specific low back pain. Lancet. 2012;379(9814):482–491.
- Berman BM. Clinical applications of acupuncture: an overview of the evidence. J Altern Complement Med. 2001;7(SUPPL. 1):S111–S1S8.
- Furlan AD, Yazdi F, Tsertsvadze A, Gross A, Van Tulder M, Santaguida L, et al. A systematic review and meta-analysis of efficacy, cost-effectiveness, and safety of selected complementary and alternative medicine for neck and low-back pain. *Evid Based Complement Alternat Med.* 2012:953139.
- Mu J, Furlan AD, Lam WY, Hsu MY, Ning Z, Lao L. Acupuncture for chronic nonspecific low back pain. *Cochrane Database of Systematic Reviews*. 2020(12).
- Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. *Arthritis Rheum*. 2012;64(6):2028–2037.
- Cecchi F, Debolini P, Lova RM, Macchi C, Bandinelli S, Bartali B, et al. Epidemiology of back pain in a representative cohort of Italian persons 65 years of age and older: the InCHIANTI study. *Spine (Phila Pa 1976)*. 2006;31(10):1149–1155.
- Li YX, Yuan SE, Jiang JQ, Li H, Wang YJ. Systematic review and meta-analysis of effects of acupuncture on pain and function in non-specific low back pain. Acupunct Med. 2020;38(4):235–243.
- National Guideline C. National Institute for Health and Care Excellence: Clinical Guidelines. Low Back Pain and Sciatica in Over 16s: Assessment and Management. London: National Institute for Health and Care Excellence (UK), NICE; 2016.
- Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. *BMJ*. 2015;350:h1225.
- Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. *Lancet*. 2018;391(10137):2368–2383.
- Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, et al. AHRQ Comparative Effectiveness Reviews. Noninvasive Treatments For Low Back Pain. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016;315(15):1624–1645.
- Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376(12):1111–1120.
- Melzack R. Acupuncture and pain mechanisms (author's transl). Anaesthesist. 1976;25(5):204–207.

- Dhond RP, Kettner N, Napadow V. Neuroimaging acupuncture effects in the human brain. J Altern Complement Med. 2007;13(6):603–616.
- Gao P, Tang F, Liu W, Mo Y. The effects of proprioceptive neuromuscular facilitation in treating chronic low back pain: a systematic review and meta-analysis. J Back Musculoskelet Rehabil. 2022;35(1):21–33.
- Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. *Pharmacol Ther*. 2006;112(2):358–404.
- Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: release and regulation of pain. *Prog Neurobiol*. 2003;69(5):313–340.
- Kolber MR, Ton J, Thomas B, et al. PEER systematic review of randomized controlled trials: management of chronic low back pain in primary care. *Can Fam Physician*. 2021;67(1):e20–e30.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- SA H. SF-36. Encyclopedia of Behavioral Medicine In: Gellman MD TJ, editors, editor. New York, NY: Springer; 2013.
- Encyclopedia of Quality of Life and Well-Being Research. SF-12v2 e, editor. Dordrecht: Springer; 2014.
- Higgins JPT TJ, Chandler J., Cumpston M., Li T., Page M.J. (Editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0.2019.
- 24. Cohen J. Statistical Power Analysis For the Behavioral Sciences. 2nd ed. New Jersey: Lawrence Erlbaum Associates; 1988.
- 25. Review Manager (RevMan). 5. 4 ed. The Cochrane Collaboration; 2020.
- MacPherson H, White A, Cummings M, Jobst KA, Rose K, Niemtzow RC. Standards for reporting interventions in controlled trials of acupuncture: the stricta recommendations. J Altern Complement Med. 2002;8(1):85–89.
- 27. White A, Cummings M, Barlas P, Cardini F, Filshie J, Foster NE, et al. Defining an adequate dose of acupuncture using a neurophysiological approach–a narrative review of the literature. *Acupunct Med.* 2008;26(2):111–120.
- MacPherson H, Maschino AC, Lewith G, Foster NE, Witt CM, Vickers AJ. Characteristics of acupuncture treatment associated with outcome: an individual patient metaanalysis of 17,922 patients with chronic pain in randomised controlled trials. *PLoS ONE*. 2013;8(10):e77438.
- Sun N, Tu JF, Lin LL, Li YT, Yang JW, Shi GX, et al. Correlation between acupuncture dose and effectiveness in the treatment of knee osteoarthritis: a systematic review. *Acupunct Med.* 2019;37(5):261–267.
- 30. Giovanardi CM, Cinquini M, Aguggia M, Allais G, Campesato M, Cevoli S, et al. Acupuncture vs. pharmacological prophylaxis of migraine: a systematic review of randomized controlled trials. *Front Neurol*. 2020;11:576272.
- Naderinabi B, Saberi A, Hashemi M, Haghighi M, Biazar G, Abolhasan Gharehdaghi F, et al. Acupuncture and botulinum toxin A injection in the treatment of chronic migraine: a randomized controlled study. *Caspian J Internal Med.* 2017;8(3):196–204.
- Schünemann HBJ, Guyatt G, Oxman A. Handbook For Grading Quality of Evidence and Strength of Recommendations. GRADE. The GRADE Working Group; 2013 Available from: https://guidelinedevelopment.org/handbook.
- 33. Schünemann HOA, Higgins J, Vist G, Glasziou P, Guyatt G. Cochrane Handbook for Systematic Reviews of Interventions Version 510 [Internet]. Chapter 11: presenting results and 'Summary of findings' tables; 2011 Available from: https://handbook-5-1.cochrane.org/chapter\_11/11\_presenting\_results\_and\_summary\_of\_findings\_tables.htm.
- 34. Cherkin DC, Eisenberg D, Sherman KJ, Barlow W, Kaptchuk TJ, Street J, et al. Randomized trial comparing traditional Chinese medical acupuncture, therapeutic massage, and self-care education for chronic low back pain. Arch Intern Med. 2001;161(8):1081–1088.
- Cherkin DC, Sherman KJ, Avins AL, Erro JH, Ichikawa L, Barlow WE, et al. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. Arch Intern Med. 2009;169(9):858–866.
- 36. Grant DJ, Bishop-Miller J, Winchester DM, Anderson M, Faulkner S. A randomized comparative trial of acupuncture versus transcutaneous electrical nerve stimulation for chronic back pain in the elderly. *Pain*. 1999;82(1):9–13.
- 37. Haake M, Müller HH, Schade-Brittinger C, Basler HD, Schäfer H, Maier C, et al. German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med. 2007;167(17):1892–1898.
- 38. Itoh K, Itoh S, Katsumi Y, Kitakoji H. A pilot study on using acupuncture and transcutaneous electrical nerve stimulation to treat chronic non-specific low back pain. *Complement Ther Clin Pract.* 2009;15(1):22–25.

- Integrative Medicine Research 12 (2023) 100972
- 39. Lin ML, Lin MH, Fen JJ, Lin WT, Lin CW, Chen PQ. A comparison between pulsed radiofrequency and electro-acupuncture for relieving pain in patients with chronic low back pain. Acupunct Electrother Res. 2010;35(3–4):133–146.
- 40. Shankar N, Thakur M, Tandon OP, Saxena AK, Arora S, Bhattacharya N. Autonomic status and pain profile in patients of chronic low back pain and following electro acupuncture therapy: a randomized control trial. *Indian J Physiol Pharmacol.* 2011;55(1):25–36.
- Yun M, Xiong N, Guo M, et al. Acupuncture at the back-pain-acupoints for chronic low back pain of peacekeepers in lebanon: a randomized controlled trial. J Musculoskelet Pain. 2012.
- 42. Yun M, Shao Y, Zhang Y, He S, Xiong N, Zhang J, et al. Hegu acupuncture for chronic low-back pain: a randomized controlled trial. J Altern Complement Med. 2012;18(2):130–136.
- 43. Leibing E, Leonhardt U, Köster G, Goerlitz A, Rosenfeldt JA, Hilgers R, et al. Acupuncture treatment of chronic low-back pain - a randomized, blinded, placebo-controlled trial with 9-month follow-up. *Pain*. 2002;96(1–2):189–196.
- 44. Molsberger AF, Mau J, Pawelec DB, Winkler J. Does acupuncture improve the orthopedic management of chronic low back pain-a randomized, blinded, controlled trial with 3 months follow up. *Pain*. 2002;99(3):579–587.
- Yeung CK, Leung MC, Chow DH. The use of electro-acupuncture in conjunction with exercise for the treatment of chronic low-back pain. J Altern Complement Med. 2003;9(4):479–490.
- Meng CF, Wang D, Ngeow J, Lao L, Peterson M, Paget S. Acupuncture for chronic low back pain in older patients: a randomized, controlled trial. *Rheumatology (Oxford)*. 2003;42(12):1508–1517.
- Zaringhalam J, Manaheji H, Rastqar A, Zaringhalam M. Reduction of chronic non-specific low back pain: a randomised controlled clinical trial on acupuncture and baclofen. *Chin Med.* 2010;5:15.
- 48. Gould D, Kelly D, Goldstone L, Gammon J. Examining the validity of pressure ulcer risk assessment scales: developing and using illustrated patient simulations to collect the data. Information point: visual Analogue Scale. J Clin Nurs. 2001;10(5):697–706.
- Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 1992;50(2):133–149.
- Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. *Spine (Phila Pa 1976)*. 1983;8(2):141–144.
- Kohlmann T, Raspe H. Hannover Functional Questionnaire in ambulatory diagnosis of functional disability caused by backaches. *Rehabilitation*. 1996;35(1):I–viii.
- Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. *Physiotherapy*. 1980;66(8):271–273.
- Tait RC, Pollard CA, Margolis RB, Duckro PN, Krause SJ. The pain disability index: psychometric and validity data. Arch Phys Med Rehabil. 1987;68(7):438–441.
- Ruta DA, Garratt AM, Wardlaw D, Russell IT. Developing a valid and reliable measure of health outcome for patients with low back pain. *Spine (Phila Pa 1976)*. 1994;19(17):1887–1896.
- Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic pain. Edinburgh (SIGN publication no. 136). 2013 [Revised edition published August 2019].
- Birch S. A review and analysis of placebo treatments, placebo effects, and placebo controls in trials of medical procedures when sham is not inert. J Altern Complement Med. 2006;12(3):303–310.
- Lund I, Lundeberg T. Are minimal, superficial or sham acupuncture procedures acceptable as inert placebo controls? *Acupunct Med.* 2006;24(1):13–15.
- Zheng CH, Huang GY, Zhang MM, Wang W. Effects of acupuncture on pregnancy rates in women undergoing in vitro fertilization: a systematic review and meta-analysis. *Fertil Steril.* 2012;97(3):599–611.
- Preuss CV, Kalava A, King KC. StatPearls. Prescription of controlled substances: benefits and risks. Treasure Island (FL): StatPearls Publishing. Copyright © 2021, Stat-Pearls Publishing LLC.; 2021.
- 60. Carpenter RW, Lane SP, Bruehl S, Trull TJ. Concurrent and lagged associations of prescription opioid use with pain and negative affect in the daily lives of chronic pain patients. J Consult Clinical Psychol. 2019;87(10):872–886.
- LaRowe LR, Powers JM, Garey L, Rogers AH, Zvolensky MJ, Ditre JW. Pain-related anxiety, sex, and co-use of alcohol and prescription opioids among adults with chronic low back pain. *Drug Alcohol Depend*. 2020;214:108171.
- 62. Witt CM, Pach D, Brinkhaus B, Wruck K, Tag B, Mank S, et al. Safety of acupuncture: results of a prospective observational study with 229,230 patients and introduction of a medical information and consent form. *Forsch Komplementarmed*. 2009;16(2):91–97.